Genovis AB (publ.) (GENO) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.059x

Based on the latest financial reports, Genovis AB (publ.) (GENO) has a cash flow conversion efficiency ratio of 0.059x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr15.90 Million ≈ $1.71 Million USD) by net assets (Skr271.52 Million ≈ $29.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GENO stock market capitalisation for the company's overall valuation and market capitalisation.

Genovis AB (publ.) - Cash Flow Conversion Efficiency Trend (2008–2025)

This chart illustrates how Genovis AB (publ.)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

Genovis AB (publ.) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Genovis AB (publ.) ranked by their cash flow conversion efficiency. Explore GENO cash flow quality score to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
PW MEDTECH GROUP DL-0001 F:PWE	N/A
Daewon Sanup Co. Ltd KQ:005710	-0.021x
Dong Hai JSC of Bentre VN:DHC	0.005x
Huangshan Tourism Development Co Ltd B SHG:900942	0.042x
Sanurhasta Mitra PT JK:MINA	0.002x
GAMCO Natural Resources Gold and Income Closed Fund NYSE:GNT	N/A
Quirin Privatbank AG F:QB7	N/A
Mineralbrunnen Überkingen-Teinach GmbH & Co. KGaA F:MUT	0.033x

Annual Cash Flow Conversion Efficiency for Genovis AB (publ.) (2008–2025)

The table below shows the annual cash flow conversion efficiency of Genovis AB (publ.) from 2008 to 2025. View today's stock price for Genovis AB (publ.) for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr271.52 Million ≈ $29.22 Million	Skr32.02 Million ≈ $3.45 Million	0.118x	-27.56%
2024-12-31	Skr227.97 Million ≈ $24.53 Million	Skr37.12 Million ≈ $3.99 Million	0.163x	-54.15%
2023-12-31	Skr190.81 Million ≈ $20.53 Million	Skr67.75 Million ≈ $7.29 Million	0.355x	+4908.05%
2022-12-31	Skr125.65 Million ≈ $13.52 Million	Skr-927.95K ≈ $-99.86K	-0.007x	-101.83%
2021-12-31	Skr113.99 Million ≈ $12.27 Million	Skr45.92 Million ≈ $4.94 Million	0.403x	+835.02%
2020-12-31	Skr87.17 Million ≈ $9.38 Million	Skr3.76 Million ≈ $404.12K	0.043x	-88.31%
2019-12-31	Skr35.62 Million ≈ $3.83 Million	Skr13.13 Million ≈ $1.41 Million	0.368x	+868.80%
2018-12-31	Skr26.07 Million ≈ $2.81 Million	Skr-1.25 Million ≈ $-134.48K	-0.048x	+89.57%
2017-12-31	Skr18.19 Million ≈ $1.96 Million	Skr-8.36 Million ≈ $-899.14K	-0.459x	+55.57%
2016-12-31	Skr15.55 Million ≈ $1.67 Million	Skr-16.08 Million ≈ $-1.73 Million	-1.034x	+43.40%
2015-12-31	Skr8.82 Million ≈ $949.39K	Skr-16.12 Million ≈ $-1.73 Million	-1.827x	-20.06%
2014-12-31	Skr14.58 Million ≈ $1.57 Million	Skr-22.19 Million ≈ $-2.39 Million	-1.522x	-303.82%
2013-12-31	Skr33.09 Million ≈ $3.56 Million	Skr-12.47 Million ≈ $-1.34 Million	-0.377x	+65.40%
2012-12-31	Skr13.63 Million ≈ $1.47 Million	Skr-14.85 Million ≈ $-1.60 Million	-1.089x	-61.46%
2011-12-31	Skr18.01 Million ≈ $1.94 Million	Skr-12.15 Million ≈ $-1.31 Million	-0.675x	+2.00%
2010-12-31	Skr15.23 Million ≈ $1.64 Million	Skr-10.48 Million ≈ $-1.13 Million	-0.688x	+45.43%
2009-12-31	Skr10.86 Million ≈ $1.17 Million	Skr-13.70 Million ≈ $-1.47 Million	-1.261x	+49.75%
2008-12-31	Skr6.68 Million ≈ $718.56K	Skr-16.76 Million ≈ $-1.80 Million	-2.510x	--

About Genovis AB (publ.)

ST:GENO Sweden Biotechnology

Market Cap

$144.32 Million

Skr1.34 Billion SEK

Market Cap Rank

#17898 Global

#306 in Sweden

Share Price

Skr20.30

Change (1 day)

-0.25%

52-Week Range

Skr16.16 - Skr23.95

All Time High

Skr87.00